Beiersdorf prohibited from making certain ad claims for Nivea product
WASHINGTON — The Federal Trade Commission announced on Wednesday that it has reached a settlement with Beiersdorf, the maker of Nivea, regarding advertising claims of its Nivea My Silhouette! skin cream.
The FTC administrative complaint charged Beiersdorf with falsely claiming that by regularly applying Nivea My Silhouette! cream to the skin, consumers could slim down. According to the complaint, Beiersdorf marketed the skin cream in nationwide television ads and through sponsored search results on Google. As part of the settlement, Beiersdorf has agreed to pay $900,000.
The proposed settlement:
Bars Beiersdorf from claiming that any product applied to the skin causes substantial weight or fat loss or a substantial reduction in body size;
Prohibits the company from claiming that any drug, dietary supplement or cosmetic causes weight or fat loss or a reduction in body size, unless the claim is backed by two randomized, double-blind, placebo-controlled human clinical studies; and
Requires that any claim regarding the health benefits of any drug, dietary supplement or cosmetic be backed by competent and reliable scientific evidence.
Daniel Myers to exit P&G for EVP role at Kraft
NORTHFIELD, Ill. — A Procter & Gamble executive will join Kraft Foods in September as its EVP supply chain, Kraft announced Thursday.
Daniel Myers — who succeeds David Brearton, now EVP and CFO of Kraft — most recently served as P&G’s VP product supply, leading the supply chain function for the company’s global hair care business, as well as coordination responsibilities for P&G’s beauty and grooming business, including manufacturing operations that supported sales in more than 170 countries.
"Daniel has extensive experience driving cost savings across complex global supply chains — in food, beverages and many other products," Kraft Foods chairman and CEO Irene Rosenfeld said. "This expertise will complement our current end-to-end cost-management initiatives, including Project SAVOR in procurement and Lean Six Sigma in manufacturing. I’m confident that Daniel’s leadership can accelerate efficiencies in our operations, which fuels our virtuous growth cycle."
La Roche-Posay launches new acne treatment
NEW YORK — In an effort to help those suffering from acne, La Roche-Posay has introduced its new Effaclar K Daily Renovating Anti-Relapse Acne Treatment 1, a daily treatment to address the ongoing, recurring life cycle of acne.
For the first time in a La Roche-Posay product, retinyl linoleate (a vitamin A derivative), salicylic acid and La Roche-Posay’s exclusive lipo-hydroxy acid (LHA) molecule are combined to help treat mild acne and prevent its reoccurrence in acne sufferers of all ages.
"While I often recommend a prescription strength retinoid for the treatment of mild acne, some of my patients complain of irritation with regular use," Dr. Hilary Baldwin said. "Incorporating an over-the-counter alternative that minimizes irritation so it can be used every day to both treat acne and prevent it from coming back is an ideal option."
Clinical testing showed a 58% reduction in overall acne imperfections and non-reoccurrence of acne imperfections (two weeks after use), the manufacturer stated.
Effaclar K Daily Renovating Anti-Relapse Acne Treatment 1 is non-comedogenic, paraben-free and dermatologist tested, even on sensitive skin. It is suitable for use on the entire face one to two times daily. Effaclar K Daily Renovating Anti-Relapse Acne Treatment 1 from La Roche-Posay has a suggested retail price of $27.90 and can be purchased at select physicians’ offices, select CVS/pharmacy stores, CVS.com, select Walgreens and Duane Reade locations, and online at Laroche-posay.us beginning in July.